Sinopharm Group Co. Ltd. has filed an updated list of directors and their roles with the Hong Kong Stock Exchange. The board consists of Non-Executive Directors Jin Bin (Chairman), Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying; Executive Directors Lian Wanyong (President) and Yang Binghua; and Independent Non-Executive Directors Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru. Jin Bin serves as Chairman of both the Nomination and Strategy and Investment Committees and is a member of the Legal and Compliance and ESG Committee. Chen Qiyu is a member of the Strategy and Investment Committee. Lian Wanyong is a member of both the Strategy and Investment Committee and the Legal and Compliance and ESG Committee. Li Peiyu is Chairman of the Remuneration Committee and a member of the Audit, Strategy and Investment, and Legal and Compliance and ESG Committees. Wu Tak Lung chairs the Audit Committee and is a member of the Remuneration Committee and Nomination Committee. Yu Weifeng leads the Legal and Compliance and ESG Committee and is a member of the Remuneration and Nomination Committees. Shi Shenghao is a member of the Audit, Nomination, and Strategy and Investment Committees. Chen Weiru is a member of the Nomination and Strategy and Investment Committees. Other directors also hold various committee roles, reflecting a broad distribution of responsibilities across governance, strategy, compliance, remuneration, and nomination functions.